



1631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John B. Harley and Judith A James

Serial No.: 08/781,296

Art Unit: 1631

Filed: January 13, 1997

Examiner: Lori A. Clow

For: ***DIAGNOSTIC AND THERAPY OF EPSTEIN-BARR VIRUS IN
AUTOIMMUNE DISEASE DISORDERS***

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Sir:

An Information Disclosure Statement, including two (2) pages of Form PTO-1449 was filed in the U.S. Patent and Trademark Office on June 21, 1999. In the Office Action mailed January 16, 2004, the Examiner requested a re-submission of the references cited in the Information Disclosure Statement filed on June 21, 1999. Accordingly, Applicants enclose copies of this Information Disclosure Statement, including two (2) pages of Form PTO-1449, sixteen documents cited therein, and the Certificate of Mailing filed on June 21, 1999.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

Respectfully submitted,

Rivka D. Monheit
Rivka D. Monheit
Reg. No. 48,731

Date: April 16, 2004

HOLLAND & KNIGHT, LLP
2000 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
404-817-8514
404-817-8588 (Fax)

U.S.S.N. 08/781,296

Filed: January 13, 1997

RESUBMISSION OF INFORMATION DISCLOSURE STATEMENT



Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Transmittal, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: April 16, 2004

1870369_v1

Chandra Russell
Chandra Russell



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John B. Harley and Judith A. James

Serial No.: 08/781,296 Group Art Unit: 1643

Filed: January 13, 1997 Examiner: Mary K. Zeman

For: **SPECIFICATION OF DIAGNOSTICS AND THERAPY OF EPSTEIN-BARR VIRUS IN AUTOIMMUNE DISORDERS**

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 08/160,604, filed November 30, 1993, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants did not submit copies of these publications with the Information Disclosure Statements filed on February 8, 1998, and January 14, 1999. These outstanding documents have not been considered and are being cited again as requested by the Examiner. As directed by Examiner Zemen in a telephone conversation on May 21, 1999,

U.S.S.N.: 08/781,296

Filed: January 13, 1997

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Applicants are not enclosing copies of the cited documents. Copies, however, will be provided upon request.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 01-2507.

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Country</u>
WO 88/09932	06-03-1988	PCT
WO 91/11718	08-08-1991	PCT

Publications

BARAKET, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," *Clin. Exp. Immunol.* 89:38-45 (1992).

BEN-CHETRIT, et al., "Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," *J. Clin. Inv.* 83:1284-1292 (1997).

CHAMBERS, et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," *Proc. Natl. Acad. Sci. USA* 82:2115-2119 (1985).

CHAN, et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," *Nucl. Acids Res.* 17:2233-2244 (1989).

DICKEY, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lups Association, Inc., Sept. 1, 1989.

ELKON, et al., "Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction," *J. of Immun.* 145:636-643 (1990).

U.S.S.N.: 08/781,296

Filed: January 13, 1997

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

HARDGRAVE, et al, "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," *Arthritis and Rheumatism* 36(7):962-970 (1993).

KAUFMAN, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Anklosing Spondylitis Pathogenesis", *Arthritis Rheum* 39:S298 (1996).

MCALLISTER, et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," *EMBO J.* 8:1177-1181 (1989).

YU

~~SCHAACK~~, "Molecular Mimicry in HLA-B-27-Related Arthritis," *Annals of Internal Medicine* 111(7):581-591 (1989).

SHARPE, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reacting with Human Anti-Sm Auto-", *FEBS Lett.* 250:585-590 (1989).

STURGESSION, et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," *J. Immun.* 3212-3218 (1988).

YAMAMOTO, et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," *J. Immun.* 140:311-317 (1988).

The Medical Letter on Drugs and Therapeutics 37(951):55-57 (1995).


Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the

U.S.S.N.: 08/781,296
Filed: January 13, 1997
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,




Patrea L. Pabst
Reg. No. 31,284

Dated: June 21, 1999
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the attached Supplemental Information Disclosure Statement is being facsimile transmitted on the date shown below to Examiner Mary K. Zeman at the U.S. Patent and Trademark Office at (703) 305-7401.



Teresa R. Spratt

Date: June 21, 1999



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number 08/781,296 Filing Date January 13, 1997 First Named Inventor John B. Harley Group Art Unit 1643 Examiner Name Mary K. Zeman Attorney Docket Number OMRF 161	
Sheet	1	of	2		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴				
	WO	91/11718	A1		08-08-1991		
	WO	88/09932			06-03-1988		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published
		BARAKET, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," <i>Clin. Exp. Immunol.</i> 89:38-45 (1992).
		BEN-CHETRIT, et al., "Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," <i>J. Clin. Inv.</i> 83:1284-1292 (1997).
		CHAMBERS, et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 82:2115-2119 (1985).
		CHAN, et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," <i>Nucl. Acids Res.</i> 17:2233-2244 (1989).
		DICKEY, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lupus Association, Inc., Sept. 1, 1989.
		ELKON, et al., "Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction," <i>J. of Immun.</i> 145:636-643 (1990).

Examinee Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet 2 of 2

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley
Group Art Unit	1643
Examiner Name	Mary K. Zeman
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		HARDGRAVE, et al, "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," <i>Arthritis and Rheumatism</i> 36(7):962-970 (1993).	
		KAUFMAN, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Ankylosing Spondylitis Pathogenesis", <i>Arthritis Rheum</i> 39:S298 (1996).	
		MCALLISTER, et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," <i>EMBO J.</i> 8:1177-1181 (1989).	
		SCHAACK, "Molecular Mimicry in HLA-B-27-Related Arthritis," <i>Annals of Internal Medicine</i> 111(7):581-591 (1989).	
		SHARPE, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reacting with Human Anti-Sm Auto-", <i>FEBS Lett.</i> 250:585-590 (1989).	
		STURGESSION, et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," <i>J. Immun.</i> 3212-3218 (1988).	
		YAMAMOTO, et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," <i>J. Immun.</i> 140:311-317 (1988).	
		The Medical Letter on Drugs and Therapeutics 37(1951):55-57 (1995).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.